Esperion Therapeutics Inc (ESPR)
2.02
+0.12
(+6.04%)
USD |
NASDAQ |
Apr 23, 09:37
Esperion Therapeutics Free Cash Flow (Quarterly): -37.06M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -37.06M |
| September 30, 2023 | -19.32M |
| June 30, 2023 | -24.75M |
| March 31, 2023 | -54.36M |
| December 31, 2022 | -42.47M |
| September 30, 2022 | -42.83M |
| June 30, 2022 | -50.53M |
| March 31, 2022 | -38.99M |
| December 31, 2021 | -57.71M |
| September 30, 2021 | -69.17M |
| June 30, 2021 | -47.87M |
| March 31, 2021 | -89.07M |
| December 31, 2020 | -81.23M |
| September 30, 2020 | -86.59M |
| June 30, 2020 | 138.81M |
| March 31, 2020 | -69.54M |
| December 31, 2019 | -50.17M |
| September 30, 2019 | -58.39M |
| June 30, 2019 | -54.24M |
| March 31, 2019 | 91.50M |
| December 31, 2018 | -28.80M |
| September 30, 2018 | -37.57M |
| June 30, 2018 | -39.20M |
| March 31, 2018 | -43.22M |
| Date | Value |
|---|---|
| December 31, 2017 | -34.87M |
| September 30, 2017 | -35.88M |
| June 30, 2017 | -26.23M |
| March 31, 2017 | -34.33M |
| December 31, 2016 | -16.40M |
| September 30, 2016 | -14.30M |
| June 30, 2016 | -7.312M |
| March 31, 2016 | -9.803M |
| December 31, 2015 | -8.677M |
| September 30, 2015 | -11.91M |
| June 30, 2015 | -8.628M |
| March 31, 2015 | -9.27M |
| December 31, 2014 | -8.228M |
| September 30, 2014 | -8.846M |
| June 30, 2014 | -6.443M |
| March 31, 2014 | -9.377M |
| December 31, 2013 | -7.544M |
| September 30, 2013 | -4.777M |
| June 30, 2013 | -3.197M |
| March 31, 2013 | -2.627M |
| December 31, 2012 | -2.366M |
| September 30, 2012 | -2.906M |
| June 30, 2012 | -2.847M |
| March 31, 2012 | -2.696M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-89.07M
Minimum
Mar 2021
138.81M
Maximum
Jun 2020
-43.97M
Average
-50.53M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
| United Therapeutics Corp | 72.00M |
| Masimo Corp | 51.80M |
| Heron Therapeutics Inc | 2.205M |
| Aldeyra Therapeutics Inc | 0.5004M |
| Ocugen Inc | -14.02M |